Clinical trials: Advanced Breast Cancer (Female)
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS)
- Trial name
- NCT03549000
- Testing
- NZV930, PDR001, NIR178
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin, and cyclophosphamide, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00074139
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Breast Neoplasms
Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer
This is an international, multicentre, double-blind, controlled, randomized phase II study comparing the efficacy and safety of fulvestrant in combination with palbociclib versus fulvestrant plus placebo in postmenopausal women…
- Trial name
- FLIPPER (NCT02690480)
- Testing
- PD-0332991 (Palbociclib), Fulvestrant
- Where
- 32 sites in Ireland, Spain
- Volunteers
- 189 people
- Sponsor
- Spanish Breast Cancer Research Group
Melanoma, Breast Cancer
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
This study evaluates whether it is safe to Focused Ultrasound Ablation (FUSA) treatments with and without PD-1 blockade and with and without intratumoral poly-ICLC. A device called the Echopulse will be used for the FUSA therapy.
- Conditions
- Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer
- Trial name
- AM-003 (NCT04116320)
- Testing
- Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Craig L Slingluff, Jr
Advanced Solid Tumours, Breast Cancer
The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
This is a phase 1, First-In-Human, open label study, trialing a new PARP (poly-ADP ribose polymerase) inhibitor medication IMP4297 in participants with advanced solid tumour.
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03507543
- Testing
- IMP4297
- Where
- 3 sites in Australia
- Volunteers
- 39 people
- Sponsor
- Impact Therapeutics, Inc.
Gastric Cancer, Triple Negative Breast Cancer
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or…
- Conditions
- Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma, Endometrial Carcinoma
- Trial name
- NCT04178460
- Testing
- Niraparib combined with MGD013
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Metastatic Breast Cancer, Locally Advanced Breast Cancer
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
The aim of the present study is to evaluate the efficacy and safety of palbociclib plus fulvestrant after failure of a combined treatment of hormonal therapy (aromatase inhibitor or tamoxifen ± LHRHa) plus a CDK4/6 inhibitor, in…
- Trial name
- NCT04318223
- Testing
- Palbociclib
- Where
- 19 sites in Italy
- Volunteers
- 168 people
- Sponsor
- Consorzio Oncotech
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Advanced Malignant Neoplasm, Advanced Melanoma
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
This trial studies the genetic analysis of blood and tissue samples from patients with cancer that has spread to other anatomic sites (advanced) or is no longer responding to treatment.
- Conditions
- Advanced Malignant Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03707574
- Testing
- Biospecimen Collection
- Where
- 144 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00096343
- Testing
- carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer, Breast Neoplasm Female
Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer
This clinical trial aims to learn whether a brief psychological therapy called Brief Acceptance and Commitment Therapy (Brief-ACT) can improve the effectiveness of neoadjuvant chemotherapy in patients with locally advanced breast…
- Conditions
- Breast Cancer, Breast Neoplasm Female, Locally Advanced Breast Cancer (LABC), Locally Advanced Breast Cancer
- Trial name
- NCT07570368
- Testing
- Brief Acceptance and Commitment Therapy, Standard Counseling, Neoadjuvant Chemotherapy
- Volunteers
- 54 people
- Sponsor
- Universitas Airlangga
Breast Cancer
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment
This is a non-interventional observational study conducted in Germany to evaluate the real-world effectiveness, tolerability, safety, and quality of life in patients with locally advanced/metastatic HR+/HER2- breast cancer…
- Trial name
- RIBANNA (NCT06311383)
- Testing
- First-line Ribociclib + endocrine therapy, First-line endocrine therapy, First-line chemtherapy
- Where
- 265 sites in Germany
- Volunteers
- 2,610 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasm Female
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
This study is a prospective, open, multi-center, single arm trial. The treatment group will receive six cycles of docetaxel, carboplatin combined with Inetetamab and Pyrotinib before surgery.
- Trial name
- neoPICD (NCT06234137)
- Testing
- Docetaxel, Carboplatin, Inetetamab
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Wang Ouchen
Breast Cancer
Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant, anastrozole, or exemestane may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount…
- Trial name
- SoFEA (NCT00253422)
- Testing
- Anastrozole, Exemestane, Fulvestrant
- Where
- 2 sites in United Kingdom
- Volunteers
- 698 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer, Lung Cancer
Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer
This is a multicenter, open-label, randomized, controlled study to test the hypothesis that ePRO monitoring added to usual care helps prolong OS or maintain and improve HRQoL in patients with unresectable advanced cancers or…
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer
- Trial name
- NCT05931445
- Testing
- e-PRO monitoring
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Comprehensive Support Project for Oncology Research
Breast Cancer
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
This randomized phase II trial is studying metronomic low-dose cyclophosphamide and methotrexate to see how well they work compared to metronomic low-dose cyclophosphamide, methotrexate, and bevacizumab in treating women with…
- Trial name
- NCT00083031
- Testing
- bevacizumab, cyclophosphamide, methotrexate
- Where
- 4 sites in United States
- Volunteers
- 57 people
- Sponsor
- Dana-Farber Cancer Institute
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Breast Cancer, Breast Cancer - Female
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
The purpose of this study is to find out if the investigational drug Ribociclib (LEE011), when taken with standard treatment (Tamoxifen +/- Goserelin) is safe and has beneficial effects in pre-menopausal and post-menopausal women…
- Conditions
- Breast Cancer, Breast Cancer - Female, Breast Cancer - Male
- Trial name
- NCT02586675
- Testing
- Tamoxifen, Ribociclib, Goserelin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
ALEXANDRIA Study Egypt
Breast Cancer (BC) is one of the most frequent cancers in women and is the most frequent cause of death in the female population.
- Trial name
- NCT03583463
- Where
- 8 sites in Egypt
- Volunteers
- 436 people
- Sponsor
- AstraZeneca